Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis

CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese health-care system perspective.PMID:38506058 | DOI:10.1080/14737167.2024.2333334
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Authors: Source Type: research